German pharma industry slams delay to orphan drug reimbursement
This article was originally published in SRA
Executive Summary
A recent Decision by the German joint federal committee (G-BA) to impose a second assessment procedure where orphan drugs are being considered for reimbursement, has been fiercely condemned by the pharmaceutical industry association, BPI. The association fears that long-winded assessment mechanism employed by the G-BA – a senior regulatory body that undertakes, among other things, health technology assessment for reimbursement purposes – will simply delay the provision of the drugs to the chronically ill.